DCF Advisers LLC Increases Stake in Evotec SE (NASDAQ:EVO)

DCF Advisers LLC increased its holdings in Evotec SE (NASDAQ:EVO) by 140.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 114,953 shares of the company’s stock after purchasing an additional 67,156 shares during the quarter. DCF Advisers LLC’s holdings in Evotec were worth $552,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in EVO. Quadrant Capital Group LLC purchased a new stake in Evotec in the 4th quarter worth approximately $25,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Evotec in the second quarter worth $87,000. Cetera Advisors LLC purchased a new position in Evotec during the 1st quarter valued at $188,000. Optiver Holding B.V. raised its holdings in Evotec by 643.1% in the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock worth $945,000 after purchasing an additional 69,936 shares in the last quarter. Finally, Mubadala Investment Co PJSC purchased a new stake in shares of Evotec in the 4th quarter worth about $53,931,000. 5.81% of the stock is owned by institutional investors.

Evotec Stock Performance

Evotec stock opened at $3.64 on Friday. The stock’s 50 day moving average is $3.85 and its 200 day moving average is $5.19. Evotec SE has a twelve month low of $2.85 and a twelve month high of $12.00. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.73 and a current ratio of 1.83.

Analysts Set New Price Targets

Several analysts have weighed in on EVO shares. Deutsche Bank Aktiengesellschaft cut Evotec from a “hold” rating to a “sell” rating in a research report on Thursday, August 8th. Morgan Stanley cut Evotec from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $15.00 to $6.00 in a research note on Monday, July 29th. Finally, HC Wainwright dropped their target price on shares of Evotec from $11.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, August 15th.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.